Limits...
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.

Schernthaner G, Mogensen CE, Schernthaner GH - Diab Vasc Dis Res (2014)

Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria guntram.schernthaner@meduniwien.ac.at.

Show MeSH

Related in: MedlinePlus

Prevalence of CKD among US adults by disease stage – National Health and Nutrition Examination Survey (NHANES), United States, 1999–2004.Data source: Saydah et al.5CKD: chronic kidney disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
getmorefigures.php?uid=PMC4230539&req=5

fig1-1479164114542802: Prevalence of CKD among US adults by disease stage – National Health and Nutrition Examination Survey (NHANES), United States, 1999–2004.Data source: Saydah et al.5CKD: chronic kidney disease.

Mentions: Chronic kidney disease (CKD) is associated with various risk factors, including cardiovascular disease, obesity and diabetes. Between 1999 and 2004, the prevalence of CKD within the general US population was estimated to be 16.8% (Figure 1);5 the most recent prevalence estimate for 2007–2012 is 15.0%.6 CKD is more prevalent in those with diabetes and older patients (Figure 1).5 Worldwide, the reported prevalence rates vary widely from 2.5% in China to 35.8% in Finland (Table 1).33


The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system.

Schernthaner G, Mogensen CE, Schernthaner GH - Diab Vasc Dis Res (2014)

Prevalence of CKD among US adults by disease stage – National Health and Nutrition Examination Survey (NHANES), United States, 1999–2004.Data source: Saydah et al.5CKD: chronic kidney disease.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2 - License 3
Show All Figures
getmorefigures.php?uid=PMC4230539&req=5

fig1-1479164114542802: Prevalence of CKD among US adults by disease stage – National Health and Nutrition Examination Survey (NHANES), United States, 1999–2004.Data source: Saydah et al.5CKD: chronic kidney disease.
Mentions: Chronic kidney disease (CKD) is associated with various risk factors, including cardiovascular disease, obesity and diabetes. Between 1999 and 2004, the prevalence of CKD within the general US population was estimated to be 16.8% (Figure 1);5 the most recent prevalence estimate for 2007–2012 is 15.0%.6 CKD is more prevalent in those with diabetes and older patients (Figure 1).5 Worldwide, the reported prevalence rates vary widely from 2.5% in China to 35.8% in Finland (Table 1).33

Bottom Line: Optimal treatment and prevention of DN may require an early, intensive, multifactorial approach, tailored to simultaneously target all modifiable risk factors.Dipeptidyl peptidase (DPP)-4 inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors lower blood glucose levels without additional risk of hypoglycaemia, and may also reduce albuminuria.Further investigation of the potential renal benefits of DPP-4 and SGLT2 inhibitors is underway.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine I, Rudolfstiftung Hospital, Vienna, Austria guntram.schernthaner@meduniwien.ac.at.

Show MeSH
Related in: MedlinePlus